Bevacizumab for Long COVID Breathing Problems
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests whether the drug bevacizumab can help people with long COVID who still have trouble breathing and reduced lung function. It is a small pilot study to see if the drug is safe and effective for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 89 years old
- You had a confirmed COVID-19 infection more than 3 months ago
- You still have trouble breathing (shortness of breath) that limits your daily activities
- A recent lung function test showed your lungs are not moving oxygen as well as they should (DLCO less than 75%)
- You are not pregnant or breastfeeding, and you are not a woman who could become pregnant
- You do not have any other serious health conditions like active cancer, uncontrolled high blood pressure, or a history of blood clots in your lungs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a structured breathing control technique can improve symptoms of long COVID. It may help by training how you breathe, but you must meet specific health and medication criteria to join.
This trial studies how the lungs’ breathing (airflow) and blood flow may be off in people with long-COVID symptoms like tiredness, shortness of breath, or trouble exercising. It may help researchers understand what’s driving symptoms and what kinds of abnormalities could be targeted.
This trial tests if bevacizumab can help people with ARDS (a serious lung condition) breathe better. It is for patients with mild, moderate, or severe ARDS who are already in the hospital.
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
This study looks at people with lingering post-COVID symptoms, especially breathing and lung-related findings, using home monitoring and medical tests. It may help researchers understand what’s driving ongoing symptoms and identify patterns that could guide better care.
This study tests whether a drug called pembrolizumab (a type of immunotherapy) can help people with ongoing neurological symptoms after COVID-19. The goal is to see if it is safe and possibly improves symptoms like brain fog, fatigue, and dizziness.
Hear when a new Dyspnea Caused by 2019-nCoV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.